Get started
Author

Noemi Hummel

Observed names: Hummel, Noemi, N Hummel, N. Hummel
ORCID: 0009-0000-5656-5025
Observed ORCID: 0009-0000-5656-5025
OpenAlex ID: A5113930139
Get real in individual participant data (IPD) meta‐analysis: a review of the methodology
2015 · Thomas P. A. Debray, Karel G. M. Moons, et al. · Research Synthesis Methods · 348
PDF
Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries
2017 · Gablu Kilcher, Noemi Hummel, et al. · Lara D. Veeken · 70
Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
2014 · Sreeraj Macha, Rüdiger Koenen, et al. · Clinical Therapeutics · 39
Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer’s Disease Continuum Using Patient-Caregiver Dyad Surveys
2024 · Amir Abbas Tahami Monfared, Artak Khachatryan, et al. · Journal of Alzheimer s Disease · 30
PDF
Climate Policy and Development
2009 · Hans Gersbach, Noemi Hummel · SSRN Electronic Journal · 28
GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world
2016 · Klea Panayidou, Sandro Gsteiger, et al. · Research Synthesis Methods · 24
PDF
Estimating Transition Probabilities Across the Alzheimer’s Disease Continuum Using a Nationally Representative Real-World Database in the United States
2023 · Amir Abbas Tahami Monfared, Shuai Fu, et al. · Neurology and Therapy · 20
PDF
Long-Term Climate Treaties with a Refunding Club
2021 · Hans Gersbach, Noemi Hummel, et al. · Environmental and Resource Economics · 15
PDF
A development-compatible refunding scheme for a climate treaty
2016 · Hans Gersbach, Noemi Hummel · Resource and Energy Economics · 14
Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease
2024 · Kristl G. Claeys, Hani Kushlaf, et al. · Orphanet Journal of Rare Diseases · 12
PDF
Prevalence Estimation of Dementia/Alzheimer's Disease Using Health and Retirement Study Database in the United States
2024 · Amir Abbas Tahami Monfared, N. Hummel, et al. · The Journal of Prevention of Alzheimer s Disease · 11
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data
2024 · Simon Shohet, Noemi Hummel, et al. · Journal of Comparative Effectiveness Research · 10
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease
2024 · Priya S. Kishnani, Barry J. Byrne, et al. · Journal of Patient-Reported Outcomes · 9
Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis
2018 · Eva-Maria Didden, Yann Ruffieux, et al. · Medical Decision Making · 9
Assessing out-of-pocket expenses and indirect costs for the Alzheimer disease continuum in the United States
2023 · Amir Abbas Tahami Monfared, Noemi Hummel, et al. · Journal of Managed Care & Specialty Pharmacy · 7
PDF
Potential Meets Practicality: AI 's Current Impact on the Evidence Generation and Synthesis Pipeline in Health Economics
2025 · Nichola R. Naylor, Noemi Hummel, et al. · Clinical and Translational Science · 6
Modelling Decline in Cognition to Decline in Function in Alzheimer’s Disease
2020 · Helene Karcher, Marina Savelieva, et al. · Current Alzheimer Research · 6
Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks
2025 · H. Henry Li, Emel Aygören-Pürsün, et al. · Allergy Asthma and Clinical Immunology · 5
Comparative Safety of Ultrasound Enhancing Agents: A Systematic Review and Bayesian Network Meta-Analysis
2024 · Ricardo De La Fuente Gonzalez, Arturo Cabra, et al. · The American Journal of Cardiology · 4
PDF
POSA283 Differential Appraisal of Functional Outcome Measures by Health Technology Assessment (HTA) Agencies When Reviewing Therapies for Rare Muscular, Skeletal and Neurodegenerative Disorders
2022 · S Raza, I Keyzor, et al. · Value in Health · 4
PDF
Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS®) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data
2024 · Priya S. Kishnani, Simon Shohet, et al. · Journal of Patient-Reported Outcomes · 3
PDF
A Systematic Literature Review On The Drivers of Effectiveness and The Efficacy-Effectiveness Gap in Hematological Malignancies with A Focus On Hodgkin’s Lymphoma
2016 · L Liu, N Hummel, et al. · Value in Health · 3
PDF
Sustainable Climate Treaties
2011 · Hans Gersbach, Noemi Hummel, et al. · SSRN Electronic Journal · 3
Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis
2026 · Roberto Salvatori, Raffaella M Colzani, et al. · The Journal of Clinical Endocrinology & Metabolism · 2
Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study
2026 · Stephan Wenninger, Hani Kushlaf, et al. · Neuromuscular Disorders · 2
PDF
Works count: 86
Citation count: 695
H-index: 11
I10-index: 12
Year
Topic
Type